Updated results of the first in man evaluation of the histone deacetylase (HDAC) inhibitor, PXD101 in cancer patients (pts).

被引：0
|
作者：
de Bono, JS
Steele, N
Vidal, L
Reid, A
Marriott, C
Tjornelund, J
Shaw, H
Plumb, J
Molife, R
Morrison, R
Fong, P
Buhl-Jensen, P
Rasmussen, A
Evans, TRJ
机构：
[1] Royal Marsden NHS Trust, Sutton, Surrey, England
[2] Beatson Oncol Ctr, Glasgow, Lanark, Scotland
[3] TopoTargets, Copenhagen, Denmark
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9121S / 9121S
页数：1
相关论文
共 50 条
  • [21] Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101
    Plumb, JA
    Finn, PW
    Williams, RJ
    Bandara, MJ
    Romero, MR
    Watkins, CJ
    La Thangue, NB
    Brown, R
    MOLECULAR CANCER THERAPEUTICS, 2003, 2 (08) : 721 - 728
  • [22] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Amanda Cashen
    Mark Juckett
    Alcee Jumonville
    Mark Litzow
    P. J. Flynn
    John Eckardt
    Betsy LaPlant
    Kristina Laumann
    Charles Erlichman
    John DiPersio
    Annals of Hematology, 2012, 91 : 33 - 38
  • [23] The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
    Anthony Tumber
    Laura S. Collins
    Kamille Dumong Petersen
    Annemette Thougaard
    Sanne J. Christiansen
    Marielle Dejligbjerg
    Peter Buhl Jensen
    Maxwell Sehested
    James W. A. Ritchie
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 275 - 283
  • [24] The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
    Tumber, Anthony
    Collins, Laura S.
    Dumong Petersen, Kamille
    Thougaard, Annemette
    Christiansen, Sanne J.
    Dejligbjerg, Marielle
    Buhl Jensen, Peter
    Sehested, Maxwell
    Ritchie, James W. A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (02) : 275 - 283
  • [25] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Warren, Katherine E.
    McCully, Cindy
    Dvinge, Henrik
    Tjornelund, Jette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 433 - 437
  • [26] The histone deacetylase inhibitor PXD101 inhibits the growth of human ovarian and colon tumour xenografts in vivo.
    Plumb, JA
    Williams, RJ
    Finn, PW
    Bandara, MJ
    Romero, MR
    Watkins, CJ
    La Thangue, NB
    Brown, R
    BRITISH JOURNAL OF CANCER, 2002, 86 : S16 - S16
  • [27] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E. Warren
    Cindy McCully
    Henrik Dvinge
    Jette Tjørnelund
    Maxwell Sehested
    Henri S. Lichenstein
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 433 - 437
  • [28] Growth inhibition of renal cancer cells by histone deacetylase inhibitors, suberoylanilide hydroxamic acid (SAHA) and PXD101
    Min, Gyeong Eun
    Hwang, Jung Jin
    Yoo, Changhee
    Kim, Mi-Joung
    Kim, Yong-Sook
    Song, Kanghyon
    Kim, Seong Cheol
    Kwon, Taek Min
    Park, Jong Yeon
    Ahn, Tai Young
    Kim, Choung-Soo
    JOURNAL OF UROLOGY, 2008, 179 (04): : 40 - 40
  • [29] The histone deacetylase inhibitor PXD101 synergises with established chemotherapeutics to inhibit tumor cell proliferation and upregulate apoptosis in vitro.
    Ritchie, J
    Tumber, A
    Edwards, N
    Finn, P
    Jensen, PB
    Sehested, M
    McLaughlin, F
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6105S - 6106S
  • [30] A simple and sensitive high-performance liquid chromatographic method for quantification of PXD101, a histone deacetylase inhibitor in human plasma
    Zhang, Ningning
    Goh, Boon Cher
    Khoo, Yok Moi
    Yeo, Winnie
    Lee, How Sung
    THERAPEUTIC DRUG MONITORING, 2007, 29 (02) : 231 - 235
12345